Citations (57)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (6)
Shogo Matsumoto, Shotaro Uehara, Hidetaka Kamimura, Naoki Cho, Hiroshi Ikeda, Satoshi Maeda, Kensuke Kagiyama, Atsunori Miyata, Hiroshi Suemizu & Kazumasa Fukasawa. (2022) Selection of the candidate compound at an early stage of new drug development: retrospective pharmacokinetic and metabolic evaluations of valsartan using common marmosets. Xenobiotica 52:6, pages 613-624.
Read now
Read now
Yang Liu, Jiaqi Zhang, Di Wu & Liran Cui. (2020) Pharmacokinetic interaction study between ligustrazine and valsartan in rats and its potential mechanism. Pharmaceutical Biology 58:1, pages 1299-1302.
Read now
Read now
Jin Ah Jung, Soo-Yun Lee, Jung-Ryul Kim, Jae-Wook Ko, Seong Bok Jang, Su Youn Nam & Wooseong Huh. (2015) A pharmacokinetic and pharmacodynamic drug interaction between rosuvastatin and valsartan in healthy subjects. Drug Design, Development and Therapy 9, pages 745-752.
Read now
Read now
Yasushi Yamazoe, Kazumi Ito & Kouichi Yoshinari. (2011) Construction of a CYP2E1-template system for prediction of the metabolism on both site and preference order. Drug Metabolism Reviews 43:4, pages 409-439.
Read now
Read now
Anne T Nies, Matthias Schwab & Dietrich Keppler. (2008) Interplay of conjugating enzymes with OATP uptake transporters and ABCC/MRP efflux pumps in the elimination of drugs. Expert Opinion on Drug Metabolism & Toxicology 4:5, pages 545-568.
Read now
Read now
M. D. Lee, E. Ayanoglu & L. Gong. (2006) Drug-induced changes in P450 enzyme expression at the gene expression level: A new dimension to the analysis of drug–drug interactions. Xenobiotica 36:10-11, pages 1013-1080.
Read now
Read now
Articles from other publishers (51)
Shunsuke Nakamura, Shingo Masuda, Shinya Oda, Daisuke Yamakawa, Shota Yamaguchi, Tamaki Ishima, Natsuka Kimura & Kenichi Aizawa. (2024) Polypharmacy-Related Shock Symptoms and Complications Associated with Phenothiazine: A Case Report. Internal Medicine.
Crossref
Crossref
Quancheng Yang, Peng Cao, Yi Lv, Hua Peng & Xuejia Zhai. (2024) Development and validation of a sensitive and simple LC-MS/MS method for simultaneous quantitation of valsartan, sacubitril and sacubitrilat in pediatric population. Journal of Pharmaceutical and Biomedical Analysis 238, pages 115829.
Crossref
Crossref
Ryota Kikuchi, Paresh P. Chothe, Xiaoyan Chu, Felix Huth, Kazuya Ishida, Naoki Ishiguro, Rongrong Jiang, Hong Shen, Simone H. Stahl, Manthena V.S. Varma, Marie‐Emilie Willemin & Bridget L. Morse. (2023) Utilization of OATP1B Biomarker Coproporphyrin‐I to Guide Drug–Drug Interaction Risk Assessment: Evaluation by the Pharmaceutical Industry. Clinical Pharmacology & Therapeutics 114:6, pages 1170-1183.
Crossref
Crossref
Paula Soria-Chacartegui, Pablo Zubiaur, Dolores Ochoa, Marcos Navares-Gómez, Houwaida Abbes, Gonzalo Villapalos-García, Alejandro de Miguel, Eva González-Iglesias, Andrea Rodríguez-Lopez, Gina Mejía-Abril, Samuel Martín-Vilchez, Sergio Luquero-Bueno, Manuel Román & Francisco Abad-Santos. (2023) Impact of Sex and Genetic Variation in Relevant Pharmacogenes on the Pharmacokinetics and Safety of Valsartan, Olmesartan and Hydrochlorothiazide. International Journal of Molecular Sciences 24:20, pages 15265.
Crossref
Crossref
Valentin Göldner, Jessica Ulke, Benedict Kirchner, Dominik Skalka, Marie Schmalz, Steffen Heuckeroth & Uwe Karst. (2023) Electrochemistry-mass spectrometry bridging the gap between suspect and target screening of valsartan transformation products in wastewater treatment plant effluent. Water Research 244, pages 120525.
Crossref
Crossref
Bo Qiu, Haojing Song, Congyang Ding, Xue Sun, Runxuan Du, Haotian Yang, Wanjun Bai & Zhanjun Dong. (2023) Pharmacokinetics and safety of highly variable valsartan in single-pill combination with amlodipine versus its generic formulation: a randomized, three-cycle, three-sequence, partially replicated crossover phase I bioequivalence clinical trial. Frontiers in Pharmacology 14.
Crossref
Crossref
Sharoen Yu Ming Lim, Basel Al Bishtawi & Willone Lim. (2023) Role of Cytochrome P450 2C9 in COVID-19 Treatment: Current Status and Future Directions. European Journal of Drug Metabolism and Pharmacokinetics 48:3, pages 221-240.
Crossref
Crossref
Marica Mezzelani, Luca Peruzza, Giuseppe d'Errico, Massimo Milan, Stefania Gorbi & Francesco Regoli. (2023) Mixtures of environmental pharmaceuticals in marine organisms: Mechanistic evidence of carbamazepine and valsartan effects on Mytilus galloprovincialis. Science of The Total Environment 860, pages 160465.
Crossref
Crossref
Solène Marie, Kayla L. Frost, Raymond K. Hau, Lucy Martinez-Guerrero, Jailyn M. Izu, Cassandra M. Myers, Stephen H. Wright & Nathan J. Cherrington. (2023) Predicting disruptions to drug pharmacokinetics and the risk of adverse drug reactions in non-alcoholic steatohepatitis patients. Acta Pharmaceutica Sinica B 13:1, pages 1-28.
Crossref
Crossref
Yasushi Yamazoe, Yoshiya Yamamura & Kouichi Yoshinari. (2022) Construction of a fused grid-based template system of CYP2C9 and its application. Drug Metabolism and Pharmacokinetics 45, pages 100451.
Crossref
Crossref
Joo Young Na, Eunsol Yang, Jae‐Hoon Kim, In Sun Kwon, Eun‐Heui Jin, Kyung‐Sang Yu, Jinsook Kim, SeungHwan Lee & Jang Hee Hong. (2022) Comparative Pharmacokinetics Between a Fixed‐Dose Combination of Pitavastatin/Valsartan 4/160 mg and the Corresponding Individual Components Through a Partial Replicated Crossover Design in Healthy Male Subjects. Clinical Pharmacology in Drug Development 11:5, pages 615-622.
Crossref
Crossref
Ling-jing Yuan, Jian-chang Qian, Xiang-yu Li, Ju Cui, Jian-ping Cai & Guo-xin Hu. (2022) Enzymatic activity on valsartan of 38 CYP2C9 variants from the Chinese population. Chemico-Biological Interactions 353, pages 109799.
Crossref
Crossref
Simona Katrnošková, Jana Gregorová & Ivan Peychl. (2021) Long-term pharmacotherapy of the primary hypertension in children. Pediatrie pro praxi 22:6, pages 393-398.
Crossref
Crossref
Salma Ben Hmida, Ichrak Bougharriou, Hana Chaabouni, Hanen Ghozzi, Khaled Zghal & Mounir Benjemaa. (2021) Can COVID-19 Be a Potential Risk Factor for Voriconazole-Induced Hyperkalemia?. European Journal of Basic Medical Sciences 11:4, pages 46-51.
Crossref
Crossref
Gonjin Song, Jee-Eun Chung, Jeong Yee, Kyung-Eun Lee, Kyungsoo Park & Hye-Sun Gwak. (2021) Effects of SLCO1B1 and SLCO1B3 Genetic Polymorphisms on Valsartan Pharmacokinetics in Healthy Korean Volunteers. Journal of Personalized Medicine 11:9, pages 862.
Crossref
Crossref
Stine RognstadCamilla L. SøraasOla U. BerglandAud HøieggenMagnus StrømmenArne HellandMimi S. Opdal. (2021) Establishing Serum Reference Ranges for Antihypertensive Drugs. Therapeutic Drug Monitoring 43:1, pages 116-125.
Crossref
Crossref
Larry C. Wienkers & Brooke M. Rock. 2021. Enzyme Kinetics in Drug Metabolism. Enzyme Kinetics in Drug Metabolism
89
112
.
Liang Jin, Yijun Pan, Natalie Lan Linh Tran, Leon N. Polychronopoulos, Aparna Warrier, Kim L. R. Brouwer & Joseph A. Nicolazzo. (2020) Intestinal Permeability and Oral Absorption of Selected Drugs Are Reduced in a Mouse Model of Familial Alzheimer’s Disease. Molecular Pharmaceutics 17:5, pages 1527-1537.
Crossref
Crossref
Aaftab S. Shaikh, Asha B. Thomas & Sohan S. Chitlange. (2020) Herb–drug interaction studies of herbs used in treatment of cardiovascular disorders—A narrative review of preclinical and clinical studies. Phytotherapy Research 34:5, pages 1008-1026.
Crossref
Crossref
Vanessa Malagnino, Urs Duthaler, Isabell Seibert, Stephan Krähenbühl & Henriette E. Meyer zu Schwabedissen. (2019) OATP1B3-1B7 (LST-3TM12) Is a Drug Transporter That Affects Endoplasmic Reticulum Access and the Metabolism of Ezetimibe. Molecular Pharmacology 96:2, pages 128-137.
Crossref
Crossref
Zahraa Jalal, Summaya Cabdi, Nazish Khan, Marina Dorsch, Navneet Gill, Fionnuala Stalker & Alan M Jones. (2019) Sacubitril/valsartan in patients with symptomatic chronic heart failure with reduced ejection fraction. Journal of Prescribing Practice 1:4, pages 182-192.
Crossref
Crossref
Boon Hooi Tan, Yan Pan, Uma Devi Palanisamy, Iekhsan Othman, Nafees Ahmed, Beow Chin Yap & Chin Eng Ong. (2019) Expression of cytochrome P450 2C9 (CYP2C9) in Escherichia coli and its functional characterization. Asia Pacific Journal of Molecular Biology and Biotechnology, pages 43-55.
Crossref
Crossref
Xinyu Chen, Mitsuru Hirano, Rudolf A. Werner, Michael Decker & Takahiro Higuchi. (2018)
Novel
18
F-Labeled PET Imaging Agent FV45 Targeting the Renin–Angiotensin System
. ACS Omega 3:9, pages 10460-10470.
Crossref
Crossref
Boon Hooi Tan, Nafees Ahemad, Yan Pan, Uma Devi Palanisamy, Iekhsan Othman, Beow Chin Yiap & Chin Eng Ong. (2018)
Cytochrome P450 2C9‐natural antiarthritic interactions: Evaluation of inhibition magnitude and prediction from
in vitro
data
. Biopharmaceutics & Drug Disposition 39:4, pages 205-217.
Crossref
Crossref
H-L Hsiao, TH Langenickel, J Petruck, K Kode, S Ayalasomayajula, U Schuehly, M Greeley, P Pal, W Zhou, MF Prescott, G Sunkara & I Rajman. (2018) Evaluation of Pharmacokinetic and Pharmacodynamic Drug-Drug Interaction of Sacubitril/Valsartan (LCZ696) and Sildenafil in Patients With Mild-to-Moderate Hypertension. Clinical Pharmacology & Therapeutics 103:3, pages 468-476.
Crossref
Crossref
Surya Ayalasomayajula, Thomas Langenickel, Parasar Pal, Sreedevi Boggarapu & Gangadhar Sunkara. (2017) Erratum to: Clinical Pharmacokinetics of Sacubitril/Valsartan (LCZ696): A Novel Angiotensin Receptor–Neprilysin Inhibitor. Clinical Pharmacokinetics 57:1, pages 105-123.
Crossref
Crossref
Ann Daly, Allan Rettie, Douglas Fowler & John Miners. (2017) Pharmacogenomics of CYP2C9: Functional and Clinical Considerations. Journal of Personalized Medicine 8:1, pages 1.
Crossref
Crossref
Surya Ayalasomayajula, Thomas Langenickel, Parasar Pal, Sreedevi Boggarapu & Gangadhar Sunkara. (2017) Clinical Pharmacokinetics of Sacubitril/Valsartan (LCZ696): A Novel Angiotensin Receptor-Neprilysin Inhibitor. Clinical Pharmacokinetics 56:12, pages 1461-1478.
Crossref
Crossref
Olga Gorlova, Sean M. Colvin, Antonio BrathwaiteFabian S. Menges, Stephanie M. Craig, Scott J. Miller & Mark A. Johnson. (2017) Identification and Partial Structural Characterization of Mass Isolated Valsartan and Its Metabolite with Messenger Tagging Vibrational Spectroscopy. Journal of the American Society for Mass Spectrometry 28:11, pages 2414-2422.
Crossref
Crossref
O. I. Avdeeva, M. N. Makarova, I. E. Makarenko, P. V. Burenkov, M. G. Shubina & V. A. Kashkin. (2016) TTOXICOLOGICAL EVALUATION OF COMBINATION OF AMLODIPINE CALCIUM CHANNELS BLOCKER WITH ANGIOTENSIN RECEPTOR BLOCKERS. Toxicological Review:1, pages 13-17.
Crossref
Crossref
Lu Gan, Xuemin Jiang, Anisha Mendonza, Therese Swan, Christine Reynolds, Joanne Nguyen, Parasar Pal, Srikanth Neelakantham, Marion Dahlke, Thomas Langenickel, Iris Rajman, Mizuki Akahori, Wei Zhou, Sam Rebello & Gangadhar Sunkara. (2016) Pharmacokinetic drug-drug interaction assessment of LCZ696 (an angiotensin receptor neprilysin inhibitor) with omeprazole, metformin or levonorgestrel-ethinyl estradiol in healthy subjects. Clinical Pharmacology in Drug Development 5:1, pages 27-39.
Crossref
Crossref
Hsiu-ling Hsiao, Thomas Heiko Langenickel, Michael Greeley, John Roberts, Wei Zhou, Parasar Pal, Sam Rebello, Iris Rajman & Gangadhar Sunkara. (2015) Pharmacokinetic drug-drug interaction assessment between LCZ696, an angiotensin receptor neprilysin inhibitor, and hydrochlorothiazide, amlodipine, or carvedilol. Clinical Pharmacology in Drug Development 4:6, pages 407-417.
Crossref
Crossref
Larry C. Wienkers & Brooke Rock. 2014. Enzyme Kinetics in Drug Metabolism. Enzyme Kinetics in Drug Metabolism
93
118
.
Meixia Chen. 2014. Handbook of Metabolic Pathways of Xenobiotics. Handbook of Metabolic Pathways of Xenobiotics
1
2
.
Mohsen A. Hedaya & Sally A. Helmy. (2013) Pharmacokinetic Interactions of Valsartan and Hydrochlorothiazide: An Open-Label, Randomized, 4-Period Crossover Study in Healthy Egyptian Male Volunteers. Clinical Therapeutics 35:6, pages 846-861.
Crossref
Crossref
Martin C. Michel, Carolyn Foster, Hans R. Brunner & Lisheng Liu. (2013) A Systematic Comparison of the Properties of Clinically Used Angiotensin II Type 1 Receptor Antagonists. Pharmacological Reviews 65:2, pages 809-848.
Crossref
Crossref
Teresa Cabaleiro, Manuel Román, Dolores Ochoa, María Talegón, Rocío Prieto-Pérez, Aneta Wojnicz, Rosario López-Rodríguez, Jesús Novalbos & Francisco Abad-Santos. (2013)
Evaluation of the Relationship between Sex, Polymorphisms in
CYP2C8
and
CYP2C9
, and Pharmacokinetics of Angiotensin Receptor Blockers
. Drug Metabolism and Disposition 41:1, pages 224-229.
Crossref
Crossref
Alexander V. LyubimovHong Liu & Richard Voorman. 2011. Encyclopedia of Drug Metabolism and Interactions. Encyclopedia of Drug Metabolism and Interactions
1
40
.
Sreeneeranj Kasichayanula, Ming Chang, Xiaoni Liu, Wen-Chyi Shyu, Steven C. Griffen, Frank P. LaCreta & David W. Boulton. (2012) Lack of Pharmacokinetic Interactions Between Dapagliflozin and Simvastatin, Valsartan, Warfarin, or Digoxin. Advances in Therapy 29:2, pages 163-177.
Crossref
Crossref
Kevin EC Meyers & Brittany Behar. (2011) Valsartan use in pediatric hypertension. Future Cardiology 7:2, pages 151-159.
Crossref
Crossref
Yoshiyuki Yamaura, Kouichi Yoshinari & Yasushi Yamazoe. (2011) Predicting Oxidation Sites with Order of Occurrence among Multiple Sites for CYP4A-mediated Reactions. Drug Metabolism and Pharmacokinetics 26:4, pages 351-363.
Crossref
Crossref
Hakuei Yamashita, Hiroo Yoda, Noriomi Kuroki, Michiko Kuwabara, Yuji Odagaki, Tetsushi Kazawa, Ryoichi Toyoshima & Taeko Maruki. (2010) Angiotensin II type 1 receptor blockers improve insulin sensitivity in patients with schizophrenia being treated with olanzapine. Psychopharmacology 213:1, pages 1-9.
Crossref
Crossref
Shu-Feng Zhou, Zhi-Wei Zhou & Min Huang. (2010) Polymorphisms of human cytochrome P450 2C9 and the functional relevance. Toxicology 278:2, pages 165-188.
Crossref
Crossref
Eugene G. Hrycay & Stelvio M. Bandiera. 2010. Pharmaceutical Sciences Encyclopedia. Pharmaceutical Sciences Encyclopedia
1
70
.
Sepuri Asha & Maravajhala Vidyavathi. (2009) Role of Human Liver Microsomes in In Vitro Metabolism of Drugs—A Review. Applied Biochemistry and Biotechnology 160:6, pages 1699-1722.
Crossref
Crossref
Ulrich M. Zanger, Miia Turpeinen, Kathrin Klein & Matthias Schwab. (2008) Functional pharmacogenetics/genomics of human cytochromes P450 involved in drug biotransformation. Analytical and Bioanalytical Chemistry 392:6, pages 1093-1108.
Crossref
Crossref
Yan-Ling He, Monica Ligueros-Saylan, Gangadhar Sunkara, Ron Sabo, Charlie Zhao, Yibin Wang, Joelle Campestrini, Françoise Pommier, Kiran Dole, Alan Marion, Willia P. Dole & Dan Howard. (2008) Vildagliptin, a Novel Dipeptidyl Peptidase IV Inhibitor, Has No Pharmacokinetic Interactions With the Antihypertensive Agents Amlodipine, Valsartan, and Ramipril in Healthy Subjects. The Journal of Clinical Pharmacology 48:1, pages 85-95.
Crossref
Crossref
S Hanafy, N J Dagenais, W F Dryden & F Jamali. (2008) Effects of angiotensin II blockade on inflammation-induced alterations of pharmacokinetics and pharmacodynamics of calcium channel blockers. British Journal of Pharmacology 153:1, pages 90-99.
Crossref
Crossref
Emi Kamiyama, Yasushi Yoshigae, Atsushi Kasuya, Makoto Takei, Atsushi Kurihara & Toshihiko Ikeda. (2007) Inhibitory Effects of Angiotensin Receptor Blockers on CYP2C9 Activity in Human Liver Microsomes. Drug Metabolism and Pharmacokinetics 22:4, pages 267-275.
Crossref
Crossref
Luis de la Cruz, Javier Romero-Vazquez, Manuel Jiménez-Sáenz, Jose Ramon Armas Padron & Juan Manuel Herrerias-Gutierrez. (2007) Severe acute hepatitis in a patient treated with anastrozole. The Lancet 369:9555, pages 23-24.
Crossref
Crossref
Toshiro Niwa, Shinji Honda, Kiyoharu Shirakawa, Yasushi Imamura, Sadayuki Osaki & Akira Takagi. (2006) Drug interaction of fluvoxamine, a selective serotonin reuptake inhibitor. Folia Pharmacologica Japonica 128:2, pages 93-103.
Crossref
Crossref